Results 1 to 10 of about 75,951 (164)

Xenogeneic humoral Graft-Vs-Host disease following hamster-to-rat bone marrow transplantation [PDF]

open access: green, 2000
Fung, JJ   +8 more
core   +3 more sources

Ruxolitinib in refractory acute and chronic graft-versus-host disease : a multicenter survey study [PDF]

open access: yes, 2020
Graft-versus-host disease is the main cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. First-line treatment is based on the use of high doses of corticosteroids.
Caballero Barrigón, D.   +35 more
core   +4 more sources

Allogeneic hematopoietic stem cell transplantation from sibling and unrelated donors in pediatric patients with sickle cell disease—A single center experience [PDF]

open access: yes, 2020
HSCT is curative in SCD. Patients with HLA-identical sibling donor have an excellent outcome ranging from 90%-100% overall and event-free survival. However, due to the lack of matched sibling donors this option is out of reach for 70% of patients with ...
Eggert, Angelika   +9 more
core   +1 more source

Immunoregulatory CD4-CD8- T cells as a potential therapeutic tool for transplantation, autoimmunity, and cancer [PDF]

open access: yes, 2013
A central objective in organ transplantation and the treatment or prevention of autoimmune disease is the achievement of antigen-specific immune tolerance.
Delisle, Jean-Sébastien   +2 more
core   +1 more source

Oral granuloma with chronic graft-vs-host disease [PDF]

open access: yes, 2021
BACKGROUND Oral mucositis is often observed with graft-versus-host disease (GVHD); however, the occurrence of oral granuloma is rare. The rapid increase in granulomatous lesions should be distinguished from malignant tumors in patients with GVHD because ...
Harada, Hiroyuki   +5 more
core  

Treosulfan-fludarabine-thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies [PDF]

open access: yes, 2020
Treosulfan-based conditioning prior to allogeneic transplantation has been shown to have myeloablative, immunosuppressive, and antineoplastic effects associated with reduced non-relapse mortality (NRM) in adults. Therefore, we prospectively evaluated the
Bader P.   +22 more
core   +1 more source

A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation [PDF]

open access: yes, 2014
The study is a randomized phase II trial investigating graft-versus-host disease prophylaxis after non-myeloablative (90 mg/m(2) fludarabine and 2 Gy total body irradiation) human leukocyte antigen matched unrelated donor transplantation.
A. A. Langston   +16 more
core   +2 more sources

Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease [PDF]

open access: yes, 2015
Effective pharmacological strategies employed in allogeneic hematopoietic cell transplantation should prevent serious chronic graft-versus-host disease and facilitate donor-recipient immune tolerance.
Asmita Mishra   +15 more
core   +2 more sources

Reduced intensity transplantation for primary immunodeficiency disorders [PDF]

open access: yes, 2010
Studies so far indicate that reduced intensity transplantation (RIT) may have an important role in treating patients with primary immunodeficiency disease (PID).
Veys, Paul
core   +3 more sources

Can Graft vs. Leukemia Effect Be Uncoupled From Graft vs. Host Disease? An Examination of Proportions [PDF]

open access: yes, 2020
Can Graft vs. Leukemia Effect Be Uncoupled From Graft vs. Host Disease?
Krieger, Elizabeth, Toor, Amir Ahmed
core   +1 more source

Home - About - Disclaimer - Privacy